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Chronic kidney disease (CKD) is strongly associated with very high mortality
rates and accelerated cardiovascular disease (CVD).
1 A main concern for
individuals with CKD is the incidence of CVD events, including coronary heart
disease, cerebrovascular disease, and peripheral vascular disease.
2-7 The proportion
of long-term and elderly patients was markedly increased in patients with CKD in
Korea and also was associated with increased prevalence of ischemic heart
disease (IHD).
8
A recent meta-analysis provided strong evidence that individuals with renal
insufficiency experience a 1.4- to 3.7-fold increased risk for CVD mortality
compared with their counterparts without renal insufficiency.
2 An independent,
graded association was observed between a reduced estimated glomerular filtration
rate (GFR) and the risk of death, cardiovascular events, and hospitalization in a large,
community based population.
6 Despite strong evidence linking CKD to worse
outcomes, however, the impact of CKD on mortality and morbidity in patients with
acute coronary syndrome (ACS) is probably underappreciated, and patients with
CKD receiving acute cardiac care may not be treated as aggressively or with
evidence-based therapies as frequently as those with normal renal function.
9-13
The present study was undertaken to evaluate the effect of renal dysfunction
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Purpose: The present study aimed to compare the clinical outcomes and to investigate prognostic factors of acute
coronary syndrome (ACS) in patients with renal dysfunction (RD). Materials and Methods: The study was a
retrospective cohort of 648 adult patients admitted with ACS between October 2005 and December 2006. The
estimated glomerular filtration rate (GFR) was classified into 4 levels: 1) normal, GFR greater than 90 mL/min/1.73
m
2; 2) mild RD, GFR of 60 to 90 mL/min/1.73 m
2; 3) moderate RD, GFR of 30 to 60 mL/min/1.73 m
2; and 4)
severe RD, GFR less than 30 mL/min/1.73 m
2. Primary end points were death and complication in hospital courses.
Secondary end points were major adverse cardiac event (MACE) during follow-up. Results: The median follow-up
was 505 ± 183 days, the mean age was 63 ± 12 years, and 71.8 percent of the group were men. A graded association
was observed between severity of RD and clinical outcomes. Severe RD independently predicted MACE [hazard
ratio, 2.731; 95% confidence interval (CI), 1.058 to 7.047, p = 0.038]. Low hemoglobin level was also an
independent risk factor for MACE (hazard ratio, 1.155; 95% CI, 1.020 to 1.307, p = 0.022). Use of lipid-lowering
therapy (hazard ratio, 0.456; 95% CI, 0.242 to 0.857, p = 0.015) was associated with reduced risk for MACE.
Conclusion: Severe RD and low hemoglobin level were an independent risk factors for the mortality and
complications of ACS, while lipid-lowering therapy was associated with reduced risk.
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INTRODUCTION(RD) on clinical outcomes that include death, complication
and major adverse cardiac event (MACE) in patients with
ACS. In addition, we explored prognostic factors of ACS
in relation to severity of RD.
Study population
This study was a retrospective cohort of consecutive 648
patients (63 ± 12 years, men 71.8%) who were admitted to
our hospital between October 2005 and December 2006,
whose discharge diagnosis by cardiac enzyme and electro-
cardiogram was ACS. Coronary angiography was perform-
ed for 642 patients. Secondary end points were analyzed in
569 patients, excluding death of 26 patients and 53 patients
with transfer to other hospitals in hospital courses or loss
during follow-up. The Chonnam National University
Hospital Ethics Committee approved this study.
Definitions
Primary end points were death and complication in hospital
courses. Secondary end points were MACE that included
cardiogenic death, myocardial infarction or stroke, and need
for emergency or elective repeat revascularization or coro-
nary artery bypass graft (CABG) during follow up. The
abbreviated Modification of Diet in Renal Disease formula
was used to estimate GFR in milliliters per minute per 1.73
m
2 from the creatinine level.
14 Estimated GFR was classi-
fied into 4 levels; 1) normal, 148 patients (51 ± 10 years,
men 76.4%), GFR ≥ 90 mL/min/1.73 m
2; 2) mild RD, 263
patients (62 ± 9.0 years, men 76.8%), 60 < GFR < 90
mL/min/1.73 m
2; 3) moderate RD, 180 patients (73 ± 8.2
years, men 61.1%), 30 < GFR < 60 mL/min/1.73 m
2; 4)
severe RD, 57 patients (71 ± 10.7 years, men 70.2%),
GFR ≤30 mL/min/1.73 m
2.
Laboratory analysis and left ventricular ejection 
fraction 
Laboratory data, which included total cholesterol (TC), low-
density lipoprotein (LDL-C), hemoglobin, high sensitive
C-reactive protein (hs-CRP), N-terminal Pro B-type natriu-
retic peptide (NT-proBNP), serum creatinine, troponin-T,
troponin-I, and creatine kinase-MB, were collected before
coronary angiography on admission. The serum levels of
TC and LDL-C were measured by standard enzymatic
methods. hs-CRP was analyzed turbidimetrically using
sheep antibodies against human CRP; this has been
validated against the Dade-Behring method.
15 The serum
NT-proBNP and cardiac enzyme levels were measured by
an electrochemiluminescence “sandwich” immunoassay
method.
16
Left ventricular ejection fraction (LVEF) was assessed
by performing transthoracic echocardiography by using a
Teicholz method before coronary angiography.
Data collection
Baseline variables were age, gender, body mass index
(BMI), and coronary risk factors, which included hyper-
tension (defined as history of hypertension, admission
blood pressure > 140 mmHg systolic or > 90 mmHg dias-
tolic), current smoking, previous history of IHD, hyperlipi-
demia (defined as history of hyperlipidemia, TC level of
240 mg/dL, or LDL-C level > 101 mg/dL), or diabetes
mellitus [defined as history of diabetes mellitus (DM) or
random blood glucose level > 200 mg/dL], clinical symp-
toms on admission (chest pain or dyspnea), and Killips
class. 
Use of certain medications was recorded on admission
[aspirin, angiotensin converting enzyme inhibitor (ACEi),
calcium channel blocker (CCB), statin, beta blocker (BB)
or heparin]. Surgical interventions [CABG, thrombolysis,
or percutaneous coronary intervention (PCI)] and coronary
care unit (CCU) stay were recorded.
The death and complications in hospital courses were
recorded [cardiogenic shock, ventricular tarchycardia (VT)
and fibrillation which needed anti-arrhythmic drug or defi-
brillation, atrioventricular (AV) block which needed tem-
porary cardiac pacemaker inserion, repeated ischemia or
myocardial infarction, cerebrovascular accident, major
bleeding, acute kidney injury (AKI), multiorgan failure,
newly developed heart failure and sepsis]. If more than
two complications in one patient were developed, types of
each complication were recorded. After discharge, newly
developed MACE during follow-up was recorded.
Statistical analysis
Continuous variables with normal distributions were ex-
pressed as means ± SD for 4 groups, based on the level of
kidney function, and they were compared with the use of
one-way ANOVA test. Categorical variables were com-
pared with the use of the chi-square test, wherever appro-
priate. The secondary survival outcome was summarized
by means of unadjusted Kaplan-Meier estimates stratified
into the 4 kidney function groups.
Cox proportional hazards modeling was used to examine
the relationship of survival with a prespecified list of risk
factors, including kidney function on MACE. Analyses
were adjusted for hypertension, DM, smoking, gender,
hyperlipidemia, age, hemoglobin, surgical interventions,
and medication (aspirin, BB, ACEi, CCB and statin). A p
value less than 0.05 was deemed as significant. Statistical
analysis was done with the Statistical Package for Social
Sciences software (SPSS 13.0 for Windows).
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Baseline characteristics
A total of 648 patients were included in the present study (ST-
segment elevation myocardial infarction; 67.7%, non-ST-
segment myocardial infarction; 27.9%, unstable angina; 4.3%).
Table 1 lists baseline characteristics of patients based on renal
function. The median follow up was 505 ± 183 days; mean
age was 63 ±12 years; 71.8% were men; and mean BMI was
24 ± 3.1. Hypertension was present in 46.3%; DM, 27.5%;
current smoking, 63.9%; hyperlipidemia, 2.3%; and 12.3%
had a history of IHD. More severe RD was associated with
older age, hypertension, DM, dyspnea and high Killip class.
However, percentages of patients who smoked at the time of
the study were lower in those with more severe RD.
Table 1.Baseline Characteristics
Baseline variables
Group I Group II Group III Group IV
p
(n = 148) (n = 263) (n = 180) (n = 57)
Age (yrs) 51 ± 10 62 ± 9.0 73 ± 8.2 71 ± 10.7 0.045
Male (%) 113 (76.4) 202 (76.8) 110 (61.1) 40 (70.2) 0.002
Body mass index (kg/m
2) 26 ± 2.9 24 ± 2.7 22 ± 2.5 22 ± 4.6 NS
Risk factor (%)
Hypertension 56 (37.8) 122 (46.4) 83 (46.1) 39 (68.4) 0.001
Diabetes mellitus 30 (20.3) 67 (25.5) 55 (30.6) 26 (45.6) 0.02
Smoking 109 (73.6) 176 (66.9) 96 (53.3) 33 (57.9) 0.001
Hyperlipidemia 2 (1.4) 8 (3.0) 4 (2.2) 1 (1.8) NS
IHD history 14 (9.7) 26 (9.9) 30 (16.7) 9 (16.1) NS
Symptom at admission (%)
Chest pain 72 (48.6) 130 (49.4) 103 (57.2) 33 (57.9) NS
Dyspnea 5 (3.4) 12 (4.6) 24 (13.3) 11 (19.3) < 0.001
SBP (mmHg) 138 ± 27 132 ± 28 128 ± 32 128 ± 46 < 0.001
DBP (mmHg) 86 ± 16 82 ± 17 80 ± 20 79 ± 29 < 0.001
Killip class 1.1 ± 0.4 1.2 ± 0.6 1.6 ± 0.9 2.3 ± 1.2 < 0.001
Diagnosis
STEMI 95 (64.2) 182 (69.2) 172 (70.6) 35 (61.4) NS
NSTEMI 43 (29.1) 71 (27.0) 47 (26.1) 20 (35.1) NS
UA 10 (6.8) 10 (3.8) 6 (3.3) 2 (3.5) NS
IHD, ischemic heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; STEMI, ST-segment elevation myocardial 
infarction; NSTEMI, non-ST-segment myocardial infarction; UA, unstable angina; NS, not significant.
Table 2.Biochemical Parameters and Left Ventricular Ejection Fraction (LVEF)
Group I Group II Group III Group IV
p
(n = 148) (n = 263) (n = 180) (n = 57)
GFR (mL/min) 115 ± 41.8 75 ± 8.5 48 ± 8.2 14 ± 11.9 < 0.001
Creatinine (mg/dL) 0.8 ± 0.2 0.9 ± 0.2 1.2 ± 0.7 2.8 ± 2.5 < 0.001
Troponin T (ng/mL) 5.0 ± 5.9 6.3 ± 8.3 6.5 ± 10.7 7.9 ± 8.6 NS
Troponin I (ng/mL) 53.6 ± 85.6 58.7 ± 77.7 59.6 ± 74.2 85.5 ± 94.4 NS
CK-MB (U/L) 101.9 ± 116.3 97.2 ± 108.4 104.6 ± 120 114.4 ± 177.9 NS
Hgb (g/dL) 14.0 ± 1.8 13.7 ± 2.7 12.5 ± 2.1 12.1 ± 2.3 < 0.001
TC (mg/dL) 185 ± 35 179 ± 37 172 ± 41 166 ± 45 0.005
LDL-C (mg/dL) 122 ± 32 118 ± 35 112 ± 36 107 ± 43 0.013
hs-CRP (mg/dL) 1.6 ± 2.5 1.6 ± 2.4 3.0 ± 4.1 3.8 ± 3.8 < 0.001
NT-proBNP (pg/mL) 798 ± 1123 1185 ± 1982 3958 ± 5854 12791 ± 13481 < 0.001
LVEF (%) 59 ± 10 57 ± 12 51 ± 14 50 ± 13 0.001
GFR, glomerular filtration rate; Hgb, hemoglobin; TC, total cholesterol; LDL, low density lipoprotein; hs-CRP, high sensitive C-reactive
protein; NT-proBNP, N-terminal pro B-type natriuretic peptide; CK-MB, creatine kinase-MB; NS, not significant.
RESULTSBiochemical parameters, LVEF, and coronary 
angiographic findings
Table 2 summarizes baseline continuous variables. Hemo-
globin, TC, LDL-C levels and LVEF were lower, while
hs-CRP and NT-proBNP levels were higher in patients
with more severe degree RD. Table 3 shows data of coro-
nary angiography according to changes of renal function.
The number of involved vessel was higher in patients with
more severe RD. In contrast, the prevalence of 1 vessel
disease was increased according to increased GFR. Other
findings such as Infarct-related artery, American College
of Cardiology / American Heart Association classification
15
and Thrombolysis In Myocardial Infarction flow were not
significantly different among the groups.
Hospital treatment on admission by kidney function
Table 4 lists medical and surgical utilization in the cohort.
The use of aspirin and CCB was not different among the
groups. The presence of moderate or severe RD was nega-
tively associated with the use of BB, ACEi, and statin. Use
of these agents was greater in the groups with preserved
renal function. In contrast, more severe RD was associated
with the use of vasopressor and diuretics. In surgical
utilization, the use of thrombolysis and CABG was not
different among the groups, but PCI was lesser in the
groups with more advanced RD.
Outcomes according to the estimated GFR
Table 5 lists in-hospital and out-hospital outcomes accord-
ing to the estimated GFR. The estimated in-hospital death
and complication rate was 0% and 4.2%, respectively, in
normal renal function. Cardiogenic shock was in 1 patient;
AV block in 4 patients; VT in 1 patient. In hospital death
and complication was 0.8% and 13.4%, respectively, for
mild RD. Cardiogenic shock was in 14 patients; major
bleeding in 1 patient; AV block in 13 patients; VT in 13
patients with complication. In hospital death and compli-
cation was 3.9% and 20.6%, respectively, for moderate
RD. Cardiogenic shock in 20 patients; AV block in 10
patients; VT in 7 patients in type of complication. The in
hospital death and complication was 3.9% and 20.6%,
respectively, for severe RD. AKI in 1 patient; Cardiogenic
shock in 19 patients; major bleeding in 2 patients; AV
block in 8 patients; VT in 6 patients in type of compli-
cation. Mean length of CCU stay was 1.9 ± 1.4 days in
patients with normal renal function and 4.5 ± 4.9 days in
those with severe RD. The incidence of MACE during
follow up was 12.7% in patients with normal renal function
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Table 3.Baseline Coronary Angiographic Findings
Variable
Group I Group II Group III Group IV
p
(n = 148) (n = 263) (n = 180) (n = 57)
Coronary angiography (%) 147 (99.3) 263 (100) 179 (99.4) 53 (93.0) 0.000
Infarct-related artery (%) NS
Left anterior descending artery 63 (50.0) 109 (44.9) 80 (47.3) 23 (44.2) NS
Left circumflex artery 20 (15.9) 39 (16.0) 25 (14.8) 9 (17.3) NS
Right coronary artery 42 (33.3) 89 (36.6) 62 (36.7) 18 (34.6) NS
Left main stem 1 (0.8) 2 (2.5) 2 (1.2) 2 (3.8) NS
Involved vessel number (%) 0.006
1 vessel 74 (58.7) 122 (50.2) 78 (46.2) 12 (23.1) 0.000
2 vessels 32 (25.4) 61 (25.1) 41 (24.3) 16 (30.8) NS
3 vessels 18 (14.3) 44 (18.1) 38 (22.5) 19 (36.5) 0.006
Left main, isolated 2 (1.6) 14 (5.8) 11 (6.5) 5 (9.6) NS
Left main, complex 0 (0) 2 (0.8) 1 (0.6) 0 (0) NS
ACC / AHA classification (%) NS
B1 44 (34.9) 88 (36.2) 44 (26.0) 16 (30.8) NS
B2 42 (33.3) 8 (28.0) 54 (32.0) 12 (23.1) NS
C 40 (31.7) 87 (35.8) 71 (42.0) 24 (46.2) NS
TIMI flow (%) NS
TIMI 0 61 (48.4) 109 (44.9) 74 (43.8) 26 (50.0) NS
TIMI 1 5 (4.0) 9 (3.7) 11 (6.5) 0 (0) NS
TIMI 2 27 (21.4) 59 (24.3) 44 (26.0) 9 (17.3) NS
TIMI 3 33 (26.2) 66 (27.2) 40 (23.7) 17(32.7) NS
ACC / AHA, American College of Cardiology / American Heart Association;  TIMI, thrombolysis in myocardial infarction;  NS, not significant.and 33.3% in those with severe RD. The incidence of
myocardial infarction and stroke were higher in patients
with more severe RD. A graded association was observed
between severity of RD and the risk of in-hospital death,
complication and CCU stay of ACS, and the incidence of
MACE during follow-up. 
Fig. 1 illustrates Kaplan-Meier survival in patients with
ACS according to renal function during follow-up. Severe
RD group showed lower probability of event-free survival
compared with the other groups.
Cox regression analysis for MACE during follow-up
Table 6 lists factors found to be significant independent
predictors of MACE in the adjusted Cox proportional
hazards model. Severe RD [hazard ratio, 2.731; 95% con-
fidence interval (CI), 1.058 to 7.047, p = 0.038], but not
Renal Dysfunction in Acute Coronary Syndrome
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Table 5.Outcomes according to the Estimated Glomerular Filtration Rate
Outcomes Group I Group II Group III Group IV p
In-hospital outcome (n = 148) (n = 263) (n = 180) (n = 57)
Death (%) 0 (0) 2 (0.8) 7 (3.9) 17 (29.8) < 0.001
Complications (%) 6 (4.2) 35 (13.4) 37 (20.6) 27 (47.4) < 0.001
Acute kidney injury 0 0 0 1
Cardiogenic shock 1 14 20 19
Major bleeding 0 1 0 2
AV block 4 13 10 8
Ventricular tachycardia 1 13 7 6
CCU stay (days) 1.9 ± 1.4 2.4 ± 2.0 3.7 ± 3.4 4.5 ± 4.9 < 0.001
Out-hospital outcome (n = 142) (n = 243) (n = 154) (n = 30)
MACE (%) 18 (12.7) 32 (13.2) 24 (15.6) 10 (33.3) 0.026
Cardiac death 1 (0.7) 2 (0.8) 4 (2.6) 0 (0) NS
Myocardial infarction 5 (3.5) 6 (2.5) 9 (5.8) 6 (20.0) 0.000
Re-PCI 16 (11.3) 30 (12.3) 17 (11.0) 6 (20.0) NS
TVR 13 (9.2) 20 (8.2) 11 (7.1) 6 (20.0) NS
Non-TVR 1 (0.7) 4 (1.6) 0 (0) 0 (0) NS
TLR 5 (3.5) 6 (2.5) 6 (3.9) 0 (0) NS
Coronary artery bypass graft 0 (0) 0 (0) 1 (0.6) 1 (3.3) NS
Stroke 0 (0) 0 (0) 0 (0) 1 (3.3) 0.027
AV, atrioventricular; CCU, coronary care unit; MACE, major adverse cardiac event; PCI, percutaneous coronary intervention; 
TVR, target vessel revascularization; TLR, target lesion revascularization.
Table 4.Hospital Treatment on Admission according to Kidney Function
Group I Group II Group III Group IV
p
(n = 148) (n = 263) (n = 180) (n = 57)
Medication (%)
Aspirin 142 (95.9) 250 (95.1) 163 (90.6) 53 (93.0) NS
Calcium channel blocker 18 (12.2) 23 (8.7) 18 (10.0) 10 (17.5) NS
Beta blocker 128 (86.5) 232 (88.2) 148 (82.2) 38 (66.7) < 0.001
ACE inhibitor 124 (83.8) 218 (82.9) 149 (82.8) 34 (59.6) < 0.001
Statin 136 (91.9) 227 (86.3) 155 (86.1) 35 (61.4) < 0.001
Vasopressor 30 (20.3) 66 (25.1) 84 (46.7) 32 (56.1) < 0.001
Diuretics 22 (14.9) 56 (21.3) 87 (48.3) 38 (66.7) < 0.001
Intervention (%)
Thrombolysis 13 (8.8) 32 (12.2) 15 (8.3) 4 (7.0) NS
PCI 124 (83.8) 232 (88.2) 161 (89.4) 43 (75.4) 0.031
CABG 1 (0.7) 7 (2.7) 1 (0.6) 1 (1.8) NS
ACE inhibitor, angiotensin converting enzyme inhibitor; PCI, percutaneous coronary intervention; CABG, coronary artery bypass 
graft; NS, not significant.Yong Un Kang, et al.
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mild and moderate RD, independently predicted death.
Other predictors of mortality were low hemoglobin level
(hazard ratio, 1.155; 95% CI, 1.020 to1.307, p= 0.022), Use
of lipid-lowering therapy (hazard ratio, 0.456; 95% CI,
0.242 to 0.857, p = 0.015) was associated with reduced
risk for MACE.
The most common cause of death in patients with CKD
was IHD.
1 Although it did not completely exclude absolute
impacts and many questions about the relationship between
CKD and mortality and morbidity after development of
ACS, previous reports suggested that more severe RD was
significant independent predictors of cardiovascular event.
2-7
Furthermore, recent studies suggested that mild renal
impairment was an independent predictor of long-term
mortality in patients with known or suspected coronary
artery disease.
9-11,18-20 The risk factors for high prevalence of
IHD in CKD patients suggested the importance of traditio-
nal risk factors (hypertension, DM, smoking, and hyperlipi-
demia) as well as novel risk factors [C-reactive protein,
fibrinogen, interleukin-6, factor VIIIc, lipoprotein(a) and
hemoglobin].
21 Consequently, Schiffrin et al.
22 reported that
aggressive risk factor modification in CKD prevented the
development of new cardiovascular event.
The present study compared the clinical outcomes and
investigated prognostic factors of ACS in patients with RD.
The result showed that more severe RD was associated
with hypertension and DM as risk factors of ACS, being
consistent with the result of Sarnak et al.
1 More severe RD
Table 6.Cox Regression Analysis for Major Adverse Cardiac Event during Follow Up
Factors Hazard ratio (95% CI) p
Normal renal function 1
Mild renal dysfunction 0.992( 0.526 - 1.871) NS
Moderate renal dysfunction 1.190 (0.534 - 2.651) NS
Severe renal dysfunction 2.731 (1.058 - 7.047) 0.038
Hypertension 0.893 (0.569 - 1.402) NS
Diabete mellitus 1.367 (0.858 - 2.179) NS
Smoking 1.275 (0.609 - 2.672) NS
Sex 1.439 (0.661 - 3.130) NS
Hyperlipidemia 0.949 (0.224 - 4.011) NS
Old age 1.010 (0.985 - 1.036) NS
Low hemoglobin 1.155 (1.020 - 1.307) 0.022
Intervention at admission
Thrombolysis 0.739 (0.317 - 1.726) NS
PCI 2.508 (0.951 - 6.616) NS
Coronary artery bypass graft 0.913 (0.518 - 1.927) NS
Cardiac medication at admission
Aspirin 1.403 (0.622 - 3.161) NS
Beta-blocker 0.908 (0.439 - 1.876) NS
ACEi 1.133 (0.587 - 2.211) NS
Calcium channel blocker 0.970 (0.453 - 2.076) NS
Statin 0.456 (0.242 - 0.857) 0.015
CI, confidence interval; PCI, percutaneous coronary intervention; ACEi, angiotensin converting enzyme inhibitor; NS, not significant.
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Fig. 1. Kaplan-Meier survival in patients with acute coronary syndrome
according to renal function during follow-up. Severe renal dysfunction group
showed lower probability of event-free survival than the other groups.
DISCUSSIONwas significantly associated with dyspnea and high Killip
class in clinical manifestations on admission and increased
NT-proBNP levels. Because increased NT-proBNP in
patients with severe RD was correlated with severity of
heart failure, left ventricle dysfunction, volume overload
and IHD, it was assumed that clinically severe
manifestations like cardiogenic shock and pulmonary
congestion with dyspnea were developed in patients with
severe RD.
23 Conversely, LDL-C level was significantly
lower in patients with more severe RD. The age-related
decline in GFR and the lower prevalence of hyperlipi-
demia might indicate increased malnutrition and inflam-
mation in patients with severe RD.
14,24
Major CVD trials often exclude patients with renal
disease, therefore, did not elucidate the effect of interven-
tions and treatment on patients with renal disease.
9-11,13 Our
analysis confirmed the use of ACEi and BB in improving
survival after development of ACS and PCI declined in
patients with severe RD, and it is highly possible that
complications like cardiogenic shock and AV block were
increased while declined in GFR.
Individuals with CKD become progressively malnou-
rished, as evidenced by low levels of albumin, prealbumin,
and transferrin, which has been suggested to be a me-
chanism for activation of inflammation.
24,25 Renal failure
causes changes in plasma components and endothelial
structure and function, thereby favoring vascular injury,
which may play a role as a trigger for inflammatory res-
ponse.
26-28 Between 30 and 50% of CKD patients have
elevated serum levels of inflammatory markers such as C-
reactive protein, interleukin-6, and tumor necrosis factor-
α. Progressive deterioration of renal function in CKD may
lead to dyslipidemia or accumulation of uremic toxins,
which can stimulate oxidative stress and inflammation, and
hence, contribute to endothelial dysfunction and progres-
sion of atherosclerosis.
22,28 Consequently, there have been
numerous studies conducted on the relationship between
inflammatory markers and CVD in CKD patients. Shlipak
et al.
21 and Menon et al.
29 reported that increased inflam-
matory marker was a risk factor of cardiovascular event.
Our present analysis confirmed that hs-CRP level and the
number of involved vessel on coronary angiography were
higher in patients with more severe RD, nevertheless, were
not significant independent predictors of MACE. 
The relationship between renal disease and cardiovas-
cular mortality has also been shown to extend to subjects
with more moderate degrees of renal functional impair-
ment. The Framingham Heart Study was among the first to
assess mild renal insufficiency and its association with
death and adverse cardiovascular events in the general
population.
30 More recently, in a large study that incorpo-
rated a diverse population of adults, Go et al.
6 clearly
demonstrated an independent and graded (inverse)
correlation between decreasing levels of renal function and
increasing event rates of cardiovascular morbidity and
death. In our study, a graded association was observed
between severity of RD and the risk of death, complication
of ACS, CCU stay, and newly developed MACE includ-
ing myocardial infarction and stroke. Severe, but not mild
and moderate, RD independently predicted MACE. Thus,
patients with more severe RD needed intense treatment
and close surveillance for improved clinical outcomes. 
Consistent with previous reports, we found anemia as a
risk factor for MACE after ACS.
31,32 The relationship
between cardiovascular event and anemia in CKD patients
was a set of complex and interrelated phenomena, and
remains to be further elucidated. Several mechanisms may
contribute to the association between anemia and adverse
clinical outcomes. Low hematocrit may predispose to
chronic myocardial hypoxia, left ventricular dilatation and
dysfunction, which leads to increased frequency of CVD.
33
In addition, anemia is associated with increased oxidative
stress since erythrocytes are a major antioxidants.
34 In this
context, correction of anemia in patients with CKD has
been shown to reduce hospitalization rate and hospital
stay.
35
Compelling data derived primarily from randomized
controlled trials have shown benefits of aspirin, ACEi, BB,
and statins, in preventing recurrent events and improving
survival after ACS developed.
36 We found that the use of
lipid-lowering therapy, but not BB and ACEi, was associat-
ed with reduced risk for MACE. It is in support of previous
reports about correction of dyslipidemia for prevention of
CVD in CKD patients.
1,21,22,37 Because dyslipidemia asso-
ciated with CKD appears to play a role in the enhanced
cardiovascular risk of these patients, treatment of dysli-
pidemia conversely may ameliorate the progression of
ACS along with its’ anti-inflammatory effects.
38
In conclusion, severe RD and low hemoglobin level
were an independent risk factors for MACE. Use of lipid-
lowering was associated with reduced risk for MACE in
ACS patients. Also, because a graded association was
observed between severity of RD and the risk of in-
hospital death, complication and CCU stay of ACS, pati-
ents with renal dysfunction need aggressive intervention
for improved prognosis and correction of cardiovascular
risk factors. 
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